Greg Thurber

Assistant Professor

University of Michigan
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Greg Thurber is an Assistant Professor at the University of Michigan, USA. His research focuses on antibody-mediated effector functions, T-cell activation through bispecific agents, and the clinical translation of antibody drug conjugates in solid tumors. Additionally, he employs machine learning techniques to predict protein properties and improve the design of T-cell targeted therapies.

Articles (43)

Antibody–drug conjugates (ADCs) are rapidly expanding in the clinical treatment of cancers, and combinations with checkpoint inhibitors further enhance antitumor activity in patients sensitive to such immunotherapy. However, a method to improve treatment durability, including cases where immunologically cold tumors limit checkpoint inhibitor activity, is needed. Here, we demonstrate that mixtures of ADCs and immune‐stimulating antibody conjugates (ISACs) enhance efficacy compared to either agent alone. Our approach utilizes two non‐competitive antibodies to increase the internalization of a tumor‐associated antigen (carcinoembryonic antigen, CEA), facilitating the entry of the toxic payload (SN‐38, a topoisomerase I inhibitor) into cancer cells. With improved FcγR engagement, the designed ISAC better delivered the immunostimulatory agent (STING agonist) into immune cells. After treatment, the average tumor volume in the combination group was ~40% of the ADC group, and ~30% of the PBS group at day 14. The side effects of combination therapy were tolerable, with an average weight loss of 7% or less after injections. We expect this approach can be readily extended to other ADCs to enhance their efficacy, including for the treatment of immunologically cold tumors.

Year:

2026

Year:

2026

Antibody-drug conjugates (ADCs) have experienced a surge in clinical approvals in the past few years. Despite this success, a major limitation to ADC efficacy in solid tumors is poor tumor penetration, which leaves many cancer cells untargeted. Co-administration of unconjugated antibody can improve tumor penetration and increase efficacy when target receptor expression is high. However, it can also reduce efficacy in low-expression tumors where ADC delivery is limited by insufficient cellular uptake. This creates an intrinsic problem because many patients express different levels of target between and within tumors. Here, we show how unconjugated High-Avidity, Low-Affinity (HALA) antibodies can automatically tune the cellular ADC delivery to match the local expression level. Using HER2 ADCs as a model, the tumor distribution of trastuzumab emtansine and trastuzumab deruxtecan co-administered with the HALA antibody was improved in vivo, translating to equal or greater ADC efficacy across a range of HER2 expression levels. Furthermore, Fc-enhanced HALA antibodies elicited a strong response in an immunocompetent mouse model. These results demonstrate that HALA antibodies can expand treatment ranges beyond high-expression targets and leverage strong immune responses.

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Antibody-Dependent Cellular Cytotoxicity (ADCC) is a key mechanism of action for humoral immune response, which is important for clinical antibodies such as trastuzumab and cetuximab. The level of ADCC is dependent on multiple properties such as antibody isotype, Fab affinity, epitope, and geometry in the immune synapse. Here, we integrated computational simulations with experiments to analyze the impacts of several key factors on ADCC, including binding affinity, target expression, hinge flexibility, and antibody valency. The kinetic model was adapted to simulate antibody cross-linking between tumor and immune-reporter cells, followed by signal activation. Given the complexity of the interactions between cells and the formation of the immunological synapse, we fitted the effective on-rates within the synapse that are hard to determine a priori . With minimal fitting, the model successfully replicated the trends of immune activation for a series of trastuzumab structural mutants. The simulations demonstrated that antibody variants with a higher likelihood of monovalent target binding, such as single-arm antibodies, as well as those with low Fab affinity and reduced hinge flexibility, increased signaling. The model was able to capture the efficacy of mixtures of antibodies with different Fc domains, which are relevant for combination treatments such as trastuzumab and pertuzumab. Interestingly, the fraction of receptors blocked with antibody combinations was more important than total receptor expression, implying restrictions on diffusion of free receptors in the synapse. Overall, the simulations showed close agreement with experimental observations, providing a tool to interpret the ADCC results and guide the design of antibody therapeutics. Graphical Abstract

Year:

2025

CanAg (CA242) is a carbohydrate antigen highly overexpressed in most gastrointestinal cancers, with minimal expression in normal tissue, making it an attractive target for antibody–drug conjugate (ADC) therapeutics in these cancers. Previous efforts to target CanAg with ADCs have shown limited clinical efficacy, possibly due to resistance to the tubulin inhibitor payloads used. IKS04 is a novel CanAg-targeting ADC comprising an anti-CanAg humanized mAb Isumab04 and a highly potent pyrrolobenzodiazepine prodrug payload. However, the use of potent payloads such as pyrrolobenzodiazepines can limit the maximum tolerated dose of ADCs, which in turn limits tumor tissue penetration and efficacy, particularly for high-expression targets such as CanAg. Coadministration of unconjugated antibody can potentially improve tumor tissue penetration, resulting in increased ADC efficacy. In this study, we evaluated the impact of Isumab04 coadministration on the distribution and efficacy of IKS04 in human tumor xenograft mouse models with different CanAg expression levels. Although the addition of the Isumab04 antibody showed minimal impact on IKS04 cell–killing activity in vitro in cells with moderate and high CanAg expression, coadministration of Isumab04 with IKS04 improved tumor tissue distribution of the ADC in both tumor spheroids and in vivo tumor models. This improved distribution correlated with increased efficacy in vivo, in which increasing doses of unconjugated antibody resulted in greater efficacy until apparent tumor saturation was reached. These results support the use of antibody coadministration to improve the efficacy of ADCs targeting high-expression antigens with highly potent payloads.

Year:

2025

Antibody-drug conjugates (ADCs) have had remarkable clinical success in recent years with multiple new approvals. However, for some ADCs, the response rates don’t closely correlate with clinical target expression. One particular ADC targeting HER2, trastuzumab deruxtecan or T-DXd, is notable due to its success at expression levels ranging from high to low and ultralow. This raises the question of the relative contributions of target-independent mechanisms on ADC efficacy in the clinic, and several such mechanisms have been proposed. However, in vitro and preclinical data have different doses and exposures, making it challenging to quantitatively extrapolate preclinical data to the clinic. In this work, we use our computational hybrid agent-based model, SimADC, to simulate target-dependent and -independent mechanisms, scaling from mice to humans. We first demonstrate that CD8+ T cells can significantly contribute to tumor regression, especially when the ADC further activates the immune cells. Next, we test target-independent payload-driven mechanisms including: 1) Fc-mediated internalization of ADC by intratumoral macrophages and payload release to neighboring cancer cells, 2) free payload circulating in the blood and re-entering the tumor, and 3) extracellular linker cleavage and payload release due to an abundance of proteases in the tumor. We find that free payload in the blood and extracellular linker cleavage had low and moderate impacts, respectively, while macrophage uptake and payload release resulted in high levels of efficacy. This is due to the macrophages’ ability to sustain free payload in the tumor. Moderate and high HER2 expression were more efficacious than target-independent mechanisms. Overall, our simulations demonstrate that moderate to high HER2 expression, immune activation, or macrophage uptake and payload release are sufficient for T-DXd tumor regression. Additionally, SimADC provides a robust framework for modeling both target-dependent and target-independent mechanisms for any ADC, providing the opportunity to engineer more effective therapeutic agents. Author Summary Cancer is one of the most prevalent diseases in the world, impacting the lives of millions of people every year. Antibody-drug conjugates (ADCs) are a form of targeted therapy that can deliver cytotoxic drugs directly to cancer cells, increasing efficacy. However, ADCs are complex to design and test, as each part of the ADC (targeting antibody, cytotoxic payload, and linker) must be optimally selected for delivery for each target and type of patient. Here, we studied ADCs using a computational model, which allowed us to simulate ADCs in varying cancer environments efficiently and economically. We validated our model using preclinical data to incorporate patient immune responses, target-independent payload release, and systemic payload uptake, allowing us to make accurate predictions in mice and extrapolate to human tumors. We compared multiple mechanisms by which ADCs can kill cancer cells to help identify the most effective methods. Besides high target expression, immune stimulation and target-independent release in the microenvironment can contribute to tumor regression. Investigating these mechanisms enables the design of ADCs and treatment regimens that maximize efficacy across a range of tumor types and target expression.

Year:

2025

CanAg (CA242) is a carbohydrate antigen highly overexpressed in most gastrointestinal cancers, with minimal expression in normal tissue, making it an attractive target for antibody–drug conjugate (ADC) therapeutics in these cancers. Previous efforts to target CanAg with ADCs have shown limited clinical efficacy, possibly due to resistance to the tubulin inhibitor payloads used. IKS04 is a novel CanAg-targeting ADC comprising an anti-CanAg humanized mAb Isumab04 and a highly potent pyrrolobenzodiazepine prodrug payload. However, the use of potent payloads such as pyrrolobenzodiazepines can limit the maximum tolerated dose of ADCs, which in turn limits tumor tissue penetration and efficacy, particularly for high-expression targets such as CanAg. Coadministration of unconjugated antibody can potentially improve tumor tissue penetration, resulting in increased ADC efficacy. In this study, we evaluated the impact of Isumab04 coadministration on the distribution and efficacy of IKS04 in human tumor xenograft mouse models with different CanAg expression levels. Although the addition of the Isumab04 antibody showed minimal impact on IKS04 cell–killing activity in vitro in cells with moderate and high CanAg expression, coadministration of Isumab04 with IKS04 improved tumor tissue distribution of the ADC in both tumor spheroids and in vivo tumor models. This improved distribution correlated with increased efficacy in vivo , in which increasing doses of unconjugated antibody resulted in greater efficacy until apparent tumor saturation was reached. These results support the use of antibody coadministration to improve the efficacy of ADCs targeting high-expression antigens with highly potent payloads.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (4)

Peter M. Tessier

University of Michigan

UNITED STATES
View details

Thomas A. Keating

Senior Vice President - Head of Research

Pretzel Therapeutics

UNITED STATES
View details

Alfred Zippelius

University of Basel

SWITZERLAND
View details

Jennifer Linderman

University of Michigan

UNITED STATES
View details